We are facing a disturbing paradox in science. We have unprecedented potential for advancements spurred by current technologies. But at the same time we are confronting flat to declining funding.
While doing somewhat-routine reporting on this year’s Senate Appropriations Committee bills, Paul Goldberg, editor and publisher of The Cancer Letter, quickly realized that he was seeing a full bipartisan rejection of President Donald J. Trump’s plan to defund and therefore dismantle biomedical research in the United States.
